Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Up to $10.57

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $10.57, but opened at $10.90. Centessa Pharmaceuticals shares last traded at $10.33, with a volume of 63,748 shares traded.

Analysts Set New Price Targets

Separately, BMO Capital Markets reissued an “outperform” rating and issued a $15.00 target price on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Centessa Pharmaceuticals Stock Down 6.0 %

The stock has a market cap of $942.91 million, a PE ratio of -5.99 and a beta of 1.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 8.00 and a current ratio of 8.00. The company’s 50-day moving average price is $10.95 and its 200 day moving average price is $8.50.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. The business had revenue of $6.85 million for the quarter. As a group, analysts forecast that Centessa Pharmaceuticals plc will post -1.83 EPS for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the transaction, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the transaction, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Harris Rotman sold 4,267 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.10, for a total value of $34,562.70. Following the transaction, the senior vice president now owns 62,625 shares of the company’s stock, valued at $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after purchasing an additional 5,037 shares during the period. Affinity Asset Advisors LLC boosted its position in shares of Centessa Pharmaceuticals by 13.0% during the 3rd quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock valued at $6,587,000 after acquiring an additional 117,368 shares during the last quarter. Platinum Investment Management Ltd. boosted its position in shares of Centessa Pharmaceuticals by 96.7% during the 3rd quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company’s stock valued at $2,184,000 after acquiring an additional 165,919 shares during the last quarter. Acuta Capital Partners LLC bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at approximately $2,092,000. Finally, Adage Capital Partners GP L.L.C. boosted its position in shares of Centessa Pharmaceuticals by 25.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock valued at $18,313,000 after acquiring an additional 580,500 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.